A 62-year-old man with a history of hypertension and type 2 diabetes mellitus is scheduled for elective laparoscopic cholecystectomy. During pre-operative assessment, the anesthesiologist is concerned about the patient's cardiovascular stability during induction. Which investigation would be most appropriate to assess the patient's cardiac reserve before selecting an induction agent?

Explanation

## Investigation of Choice to Assess Cardiac Reserve Pre-operatively ### Clinical Context A 62-year-old with hypertension and type 2 diabetes mellitus is undergoing elective laparoscopic cholecystectomy. The anesthesiologist is specifically concerned about **cardiovascular stability during induction** and wants to assess **cardiac reserve** — i.e., the functional capacity of the heart (ejection fraction, wall motion, valvular status) — before selecting an induction agent. Different induction agents have markedly different hemodynamic profiles: - **Propofol**: Significant vasodilation and myocardial depression — poorly tolerated in reduced EF - **Thiopentone**: Reduces SVR and myocardial contractility - **Etomidate**: Hemodynamically neutral — preferred when EF is reduced or cardiac reserve is compromised - **Ketamine**: Sympathomimetic — maintains or increases BP/HR; useful in low-output states ### Why Transthoracic Echocardiography (TTE) Is the Investigation of Choice **Key Point:** When the clinical question is specifically about **cardiac reserve** — the functional capacity of the myocardium — transthoracic echocardiography (TTE) is the most appropriate investigation. TTE provides: - **Ejection fraction (EF)**: Directly quantifies systolic function; EF <40% mandates etomidate over propofol/thiopentone - **Wall motion abnormalities**: Identifies regional ischemia or prior infarction not apparent on resting ECG - **Valvular assessment**: Aortic stenosis or mitral regurgitation significantly alters induction strategy - **Diastolic dysfunction**: Common in hypertensive diabetic patients; affects fluid management and agent selection - **Estimated filling pressures**: Guides hemodynamic management intra-operatively **High-Yield:** In a patient with hypertension and diabetes — both of which cause LV hypertrophy, diastolic dysfunction, and subclinical cardiomyopathy — a resting ECG may be entirely normal despite significantly impaired cardiac reserve. TTE is the only modality that directly quantifies the functional parameters needed to select the safest induction agent. ### Why Other Investigations Are Not the Best Answer Here | Investigation | Limitation in This Context | |---|---| | **12-lead ECG** | Screens for arrhythmias and ischemic changes; does NOT quantify EF or cardiac reserve | | **Coronary angiography** | Invasive; indicated for ACS/unstable angina, not routine elective pre-op assessment | | **Cardiac biomarkers (troponin, BNP)** | Useful for acute MI rule-out or HF monitoring; not a direct measure of cardiac reserve for induction planning | **Clinical Pearl (Harrison's / ACC-AHA Guidelines):** For patients with known or suspected cardiac dysfunction undergoing intermediate-to-high-risk surgery, echocardiography is recommended to assess LV function when clinical assessment is insufficient. The ACC/AHA 2014 perioperative guidelines support TTE when functional capacity cannot be determined and results will change management — which is precisely the scenario described here. **Bottom Line:** The stem explicitly asks about assessing **cardiac reserve** to guide induction agent selection. This is a functional question answered by TTE (EF, wall motion, valvular status), not a screening question answered by ECG. Etomidate would be preferred if TTE reveals reduced EF or significant structural disease.